Search Results
+Na] + Flavonoids 10 Liquiritigenin C 15 H 12 O 4 FURUXTVZLHCCNA-AWEZNQCLSA-N 5.96 257.0808213 257.081 [M+H] + Flavonoids 11 Licochalcone B C 16 H 14 O 5 DRDRYGIIYOPBBZ-XBXARRHUSA-N 6.21 287.0911089 287.091 [M+H] + Chalcones 12 Pseudoginsenoside F11 C 42 H 72 O 14
colorectal cancer in ulcerative colitis: a case-control analysis with blinded prospective pathology review. Gastroenterology, 2006, 130 (Suppl.) , O14. Rothe J. A. Increased
Control 0 13.5 0.9977 0 – Cu(nor) 2 ·H 2 O 1.4 12
−Glc+H] + ; 435.11 [M−Glc−Rha+H] + ; 273.05 [M−2Glc−Rha+H] + C 33 H 42 O 19 Naringin 4′-glucoside 7 28.24 226, 282 603.10 [M+Na] + 435.11 [M−Rha+H] + ; 273.06 [M−Glc−Rha+H] + C 27 H 32 O 14 Narirutin 8 a 29.89 227, 282 603.10 [M+Na] + 435.11 [M−Rha+H] + ; 273
. Biochem. 8 , 109–112. Hofmanová O 1,4-Benzoxazine derivatives in plants Eur. J. Biochem. 1969 8
A myeloma multiplex kezelési javaslata 2024-ben
How we treat myeloma in 2024
(Dara)MPV Melphalan 6–9 mg/m 2 p.o. 1–4. nap San Miguel, N Engl J Med. 2008 (1) Bortezomib 1,3 mg/m 2 sc. 1., 8., 22., 29. (az első ciklusban heti 2x, azaz 1., 4., 8., 11., 22., 25., 29., 32.) nap PFS 21,7 hónap, 3 éves OS 68,5% Prednisolon 40–60 mg
Magnesium sulphate complexes with hexamethylenetetramine and 1,10-phenanthroline
Thermal, structural and spectroscopic properties
.4691(17) S11–O11 1.4722(19) S11–O14 1.4756(19) S11–O12
59 16.040 [M − H]−1 578.16356 2.46 577.15778,431.10046,285.04150,283.02557 C27 H30 O14 kaempferitrin 60 16.054 [M − H]−1 448.10056 3.66 447.09500,285.04147,284.03372,151.00412 C21 H20 O11 Cynaroside 61 16.066 [M − H]−1 464.09548 3.81 463
.47(72) O1–H1···O17 0.820(11) 2.864(13) 3.605(16) 151.16(76) O2–H2···O14 0
011470o . 14. King , SB 2004 Free Rad Biol Med 37 : 737 10.1016/j.freeradbiomed.2004
